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Abstract
Tight control of blood glucose is the most important strategy for the treatment of diabetes mellitus. Here, we investigated the beneficial effects
of Welsh onion on fasting and postprandial hyperglycemia. Inhibitory activities of hot water extracts from the green stalk and white bulb, which
are the edible portions of the Welsh onion, and the fibrous root extract against yeast α-glucosidase were measured in vitro. To study the effects
of Welsh onion on postprandial hyperglycemia, a starch solution (1 g/kg) with and without Welsh onion fibrous root extract (500 mg/kg) or acarbose
(50 mg/kg) was administered to streptozotocin-induced diabetic rats after an overnight fast. Postprandial plasma glucose levels were measured and 
incremental areas under the response curve were calculated. To study the hypoglycemic effects of chronic feeding of Welsh onion, five-week-old
db/db mice were fed an AIN-93G diet or a diet containing either Welsh onion fibrous root extract at 0.5% or acarbose at 0.05% for 7 weeks
after 1 week of adaptation. Fasting plasma glucose and blood glycated hemoglobin were measured. Compared to the extract from the edible portions
of Welsh onion, the fibrous root extract showed stronger inhibition against yeast α-glucosidase, with an IC50 of 239 μg/mL. Oral administration
of Welsh onion fibrous root extract (500 mg/kg) and acarbose (50 mg/kg) significantly decreased incremental plasma glucose levels 30-120 min 
after oral ingestion of starch as well as the area under the postprandial glucose response curve, compared to the control group ( P< 0.01). The 
plasma glucose and blood glycated hemoglobin levels of the Welsh onion group were significantly lower than those of the control group (P <
0.01), and were not significantly different from those fed acarbose. Thus, we conclude that the fibrous root of Welsh onion is effective in controlling
hyperglycemia in animal models of diabetes mellitus. 
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Introduction6)
Type 2 diabetes is characterized as an imbalance in carbohy-
drate, fat, and protein metabolism, primarily due to increased 
insulin resistance and relatively impaired insulin secretion [1]. 
Tight control of blood glucose levels and the prevention of 
diabetic complications are the major goals in diabetes treatment 
[2,3]. Controlling hyperglycemia is also the most important factor 
for reducing risks of diabetic complications [3]. Both fasting and 
postprandial glucose are critical in achieving long-term proper 
control of hyperglycemia in diabetic patients [4]. 
Agents with α-glucosidase inhibitory activity, such as acarbose 
and miglitol, are hypoglycemic agents that are effective in 
alleviating both fasting and postprandial hyperglycemia [5,6]. α
-Glucosidase inhibitors partially inhibit digestion of dietary 
carbohydrates in the small intestine, resulting in a delayed 
increase in blood glucose and insulin after a meal. From this 
point of view, numerous studies have been performed to identify 
more effective and safer inhibitors of α-glucosidase from natural 
materials, including plants [7-11]. Natural materials such as 
Touchi, fermented soybean [7], Rhus Chinensis galls [8], Rosa 
damascena Mill. Flowers [9], Saururus chinensis Baill leaves 
[10], and guava leaves [11] have shown potent inhibitory activity 
against  α-glucosidase activity.
The Welsh onion (Allium fistulosum L.) belongs to the genus 
Allium, which is composed of edible perennial plants, including 
shallots, garlic, chives, and leeks. The edible portions of the 
Welsh onion are the green stalk and the white bulb, which are 
used as ingredients in Asian cuisine, especially in East and 
Southeast Asia. In contrast, the white fibrous root is usually 
discarded. The edible portion of Welsh onion has been reported 
to show hypolipidemic [12] and antioxidant effects in rats fed 
a high-fat, high sucrose diet [13]. Dyslipidemia is one 
characteristic of diabetes [14], and hyperglycemia in diabetes 
This  work  was  supported  by  the  2010  Inje  University  research  grant.
§ Corresponding  Author:  Jung-In  Kim,  Tel.  82-55-320-3236,  Fax.  82-55-321-0691,  Email.  fdsnkiji@inje.ac.kr
Received:  August  13,  2010,  Revised:  November  14,  2010,  Accepted:  November  19,  2010 
ⓒ2010  The  Korean  Nutrition  Society  and  the  Korean  Society  of  Community  Nutrition
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which  permits  unrestricted  non-commercial  use,  distribution,  and  reproduction  in  any  medium,  provided  the  original  work  is  properly  cited.Min-Jung Kang et al. 487
leads to increase oxidative stress, which plays an important role 
in the progression of diabetes [15,16]. Thus, the Welsh onion 
could be beneficial for diabetes because of its hypolipidemic and 
antioxidant effects.
However, few studies on the hypoglycemic effects of Welsh 
onion have been reported. Additionally, the physiological effects 
of the edible portion and fibrous root of the Welsh onion have 
not been compared in a scientific study. Thus, we investigated 
the α-glucosidase inhibitory activities of the edible portion and 
fibrous root of the Welsh onion in vitro. The fibrous root, which 
exerted strong α-glucosidase inhibition in vitro, was further 
studied to examine potential beneficial effects on fasting and 
postprandial hyperglycemia in an animal model of diabetes. 
These effects were compared with those of acarbose to evaluate 
its possible use as a hypoglycemic agent.
Materials and Methods
Preparation of Welsh onion extract
Welsh onions were obtained from a local market in Busan, 
Korea. The green stalk and white bulb (edible portion) along 
with the fibrous root were separated using a knife. The edible 
portion and fibrous root were freeze-dried, powdered, and 
extracted with 20 volumes of water at 100℃ for 2 h [17]. The 
solvent was removed by rotary evaporation at 80℃. The extract 
yields of the edible portion and fibrous root were 7.7% and 
11.0%, respectively. The dry extract was used for an in vivo 
study, and was redissolved in dimethylsulfoxide (DMSO) at a 
concentration of 5 mg/mL. DMSO and all other chemical 
reagents used in this study were purchased from Sigma Chemical 
Co. (St. Louis, MO, USA).
Enzyme inhibition assay
Yeast α-glucosidase inhibitory activity was determined using 
the chromogenic method developed by Watanabe et al. [18] with 
a microplate reader (model 550, Bio-Rad, Hercules, CA, USA). 
Yeast α-glucosidase (0.7 U, Sigma Chemical Co.) dissolved in 
100 mM phosphate buffer (pH 7.0) containing 2 mg/mL of 
bovine serum albumin and 0.2 mg/mL of NaN3, was used as 
the enzyme, and 5 mM p-nitrophenyl-α-D-glucopyranoside in the 
same buffer (pH 7.0) was used as a substrate solution. The final 
extract concentrations of the edible portion and fibrous root of 
the Welsh onion along with acarbose, a positive control, were 
25, 50, 100, 250, and 500 μg/mL. Measurements were performed 
in triplicate, and the IC50 value, the concentration of the root 
extract that resulted in 50% inhibition of maximal activity, was 
determined.
Measurement of postprandial blood glucose response in 
streptozotocin-induced diabetic rats 
Male Sprague-Dawley rats weighing 220-250 g were purchased 
from Bio Genomics, Inc. (Seoul, South Korea). All rats were 
fed a commercial chow (Samyang Co., Seoul, Korea) ad libitum 
for 2 weeks after arrival. The animals received an intraperitoneal 
injection of streptozotocin (STZ; 60 mg/kg) in citrate buffer at 
pH 4.5 [19]. Blood samples were taken from the tail tip after 
1 week, and blood glucose concentrations were measured using 
a glucometer (Glucotrend, Roche Diagnostics, UK). Animals 
were considered diabetic and included in the study if fasting 
blood glucose levels exceeded 200 mg/dL. The animals were 
maintained under standard laboratory conditions of 24 ± 5℃ and 
55 ± 5% relative humidity with a regular 12/12-h light/dark cycle. 
The rats (n = 18) were randomly divided into three groups. After 
an overnight fast, the rats were given soluble starch (1 g/kg) 
alone or starch with an extract of the Welsh onion fibrous root 
(500 mg/kg) or acarbose (50 mg/kg, Glucobay; Bayer, Korea) 
by gastric intubation [20]. Blood samples were collected from 
the tail tip after 30, 60, 120, 180, and 240 min and centrifuged 
(1,000 g, 15 min). Plasma glucose was measured by enzymatic 
methods [21] using a commercial kit (Yeongdong Co. Seoul, 
Korea). Glucose levels were expressed as increments from 
baseline, and areas under the response curves (AUC) were 
calculated using the trapezoidal rule.
Measurement of control of fasting hyperglycemia in db/db mice
Five-week-old male C57BL/KsJ-db/db mice (n = 21) were 
purchased from SLC Japan (Shizuoka, Japan). After 1 week of 
adaptation, during which time the animals had free access to 
commercial chow, they were randomly divided into control, 
Welsh onion, and acarbose treatment groups. The mice in the 
control group were fed an AIN-93G diet composed of 39.8% 
cornstarch, 20% casein, 13.2% dextrinized cornstarch, 10% 
sucrose, 7% soybean oil, 5% Alphacel, 3.5% mineral mixture, 
1% vitamin mixture, 0.3% l-cystine, 0.25% choline bitartrate, and 
0.0014% tert-butyl hydroquinone [22], ad libitum for 7 weeks. 
The Welsh onion and acarbose groups were fed the same diet 
supplemented with 0.5% (wt/wt, final concentration) hot water 
extract of the Welsh onion fibrous root and 0.05% acarbose, 
respectively. At the end of the experimental period, the mice 
were sacrificed by heart puncture after an overnight fast. Blood 
glycated hemoglobin (HbA1C) was measured using a chromato-
graphic assay kit (BioSystems, Barcelona, Spain) [23]. Plasma 
glucose was measured by enzymatic methods [21] using an assay 
kit (Yeongdong Co., Seoul, Korea). 
The experiments were performed according to the guidelines 
of animal experimentation, as approved by the Animal Resource 
Center at Inje University, Korea.488 Hypoglycemic effects of welsh onion
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Fig. 1. Inhibitory activities of Welsh onion  against yeast α-glucosidase.  The 
inhibitory activities of the hot water extracts of the edible portions (green stalk and 
white bulb) and fibrous root of Welsh onion as well as acarbose were measured 
at concentrations of 25, 50, 100, 250, and 500 μg/mL. ●, edible part (green stalk 
and white bulb) of Welsh onion; ○, fibrous root of Welsh onion; ■, acarbose. Values 
represent  means ± SD  of  triplicate  measurements.
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Fig. 2. Increase in blood glucose after administration of Welsh onion extract 
in STZ-induced diabetic rats. Control group (●): Starch (1 g/kg) was administered 
orally  to  streptozotocin-induced  diabetic  rats  after  an  overnigh t  fa s t. W e ls h  o n io n
group (○): Starch (1 g/kg) plus water extract of fibrous root of Welsh onion (500 
mg/kg) was administered orally to rats after an overnight fast. Acarbose group (■): 
Starch (1 g/kg) plus acarbose (50 mg/kg) was administered orally to rats after an 
overnight fast.  Values  represent  means ± SD (n = 6).  Means  that  do  not  share  a 
common  letter  are  significantly  different  at  P < 0.01  (**).
Group Control Welsh onion Acarbose
Initial body weight (g) 22.3 ± 1.4
ns2) 22.2 ± 1.7 21.9 ± 1.6
Final body weight (g) 44.1 ± 1.5
ns 43.2 ± 2.0 41.7 ± 1.8
Weight gain (g) 0.44 ± 0.02
ns 0.43 ± 0.06 0.41 ± 0.05
Food intake (g) 4.4 ± 0.4
ns 4.4 ± 0.3 4.2 ± 0.5
Feed efficiency ratio (%)
1) 10.1 ± 1.2
ns 9.7 ± 1.3 9.7 ± 1.6
The control group was fed a standard AIN-93G diet, whereas the Welsh onion and 
acarbose groups were fed either a diet containing 0.5% hot water extract of Welsh 
onion fiberous root (wt/wt, final concentrations) or 0.05% acarbose ad libitum for 
7  weeks.  Values  represent  means ± SD  (n = 7).
1) Feed  efficiency  ratio  (%) = (Body  weight  gain  [g/day]/food  intake [ g / d a y ] )×1 0 0
2) Not  significant
Table 2. Body weight, food intake, and feed efficiency ratio of db/db mice
Group AUC (mg․min/dL)
Control 11,147 ± 1,651
a
Welsh onion  5,165 ± 894
b
Acarbose 3,752 ± 681
b
C o n t ro l g ro u p : S t a rc h  (1  g /k g ) w a s  a d m in is te re d  o ra lly  t o  s t re ptozotocin-induced 
diabetic rats after an overnight fast. Welsh onion group: Starch (1 g/kg) plus water 
extract of the fibrous root of Welsh onion (500 mg/kg) was administered orally to 
rats after an overnight fast. Acarbose group: Starch (1 g/kg) plus acarbose (50 mg/kg) 
was administered orally to rats after an overnight fast. Values represent means ±
SD (n = 6). Means that do not share a common superscript are significantly different 
at  P < 0.01.
Table 1. Area under the glucose response curve (AUC) of STZ-induced diabetic
rats
Statistical analysis
All data are expressed as the mean ± standard deviation (SD). 
All statistical analyses were performed using SAS software (ver. 
9.2). Differences among groups were assessed by one-way 
analysis of variance (ANOVA) and a post hoc Tukey test (P
<0 . 0 5 ) .
Results
Inhibition of α-glucosidase activity in vitro
The inhibitory activities of water extracts of Welsh onion 
against yeast α-glucosidase  in vitro are shown in Fig. 1. The 
water extracts of the edible portion and fibrous root of the Welsh 
onion inhibited yeast α-glucosidase activity by 15.5% and 62.1% 
at the concentration of 500 μg/mL, respectively, and both extracts 
inhibited enzyme activity in a dose-dependent manner. Acarbose, 
an α-glucosidase inhibitor that is used as an oral hypoglycemic 
agent, inhibited enzyme activity by 31.2% at the same 
concentration. The IC50 value of the fibrous root extract was 
estimated as 239 μg/mL.
Amelioration of postprandial blood glucose in STZ-induced 
diabetic rats
The fibrous root extract of the Welsh onion, which showed 
strong α-glucosidase inhibition in vitro, was further studied for 
α-glucosidase inhibitory activity in vivo. Fig. 2 shows plasma 
glucose responses to a single oral dose of starch (1 g/kg) alone, 
the Welsh onion root  extract (500 mg/kg), and acarbose (50 
mg/kg) in STZ-induced diabetic rats. The consumption of the 
fibrous root extract or acarbose significantly decreased incremental 
plasma glucose levels at 30, 60, and 120 min (P < 0.01). 
Incremental plasma glucose levels in the acarbose group were 
significantly lower than those of the control group at 180 min 
(P< 0.05). Incremental plasma glucose levels in the Welsh onion 
group were not significantly different from the acarbose group.
The AUCs for glucose responses in the Welsh onion (5,165
± 894 mg·min/dL) and acarbose groups (3,752 ± 681 mg·min/dL) 
were significantly decreased, compared to the control group 
(11,147 ± 1,651 mg·min/dL, P < 0.01; Table 1). There were no 
significant differences between the AUCs of the Welsh onion Min-Jung Kang et al. 489
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Fig. 3. Hypoglycemic effects of Welsh onion extract in db/db mice. A. Fasting 
plasma glucose; B. Blood glycated hemoglobin (HbA1C). Values represent means ±
SD (n = 7). Means that do not share a common letter are significantly different at 
P < 0.01.
group and those of the acarbose group.
Alleviation of fasting hyperglycemia in db/db mice
The consumption of fibrous root extracts from Welsh onion 
(0.5% of diet, wt/wt) or acarbose (0.05% of diet, wt/wt) did not 
significantly influence body weight, food intake, or feed 
efficiency ratio in db/db mice (Table 2). Consumption of the 
fibrous root extract significantly reduced plasma glucose (326
± 34 mg/dL) compared to the control group (480 ± 44 mg/dL, 
P < 0.01; Fig. 3). Plasma glucose was significantly reduced in 
the acarbose group (279 ± 29 mg/dL) as compared to the control 
group (P < 0.01). There were no significant differences between 
the plasma glucose levels of the Welsh onion and acarbose groups. 
Consumption of the fibrous root extract of the Welsh onion or 
acarbose significantly decreased blood HbA1C  (6.0 ± 0.5% and 
5.3 ± 0.4%, respectively) compared to the control group (7.8 ±
0.6%,  P < 0.01). There was no significant difference between 
blood HbA1C levels in the Welsh onion and acarbose groups.
Discussion
The edible portions of the Welsh onion (the green stalk and 
white bulb) are widely used in Asian cuisine for flavoring in 
countries such as Korea, Japan, and China. However, the fibrous 
root of the Welsh onion is typically discarded as a waste product. 
We found that the yeast α-glucosidase inhibitory activity of the 
fibrous root extract of Welsh onion was twice as strong as that 
of acarbose, and four times stronger than the edible portion of 
the Welsh onion at a concentration of 500 μg/mL  in vitro.
Although α-glucosidase inhibitors are common oral hypoglycemic 
agents, the chronic use of these agents can lead to gastrointestinal 
side effects such as flatulence, vomiting, and diarrhea [24].
  Thus, 
many investigators have performed studies to discover α
-glucosidase inhibitors from natural products with reduced side 
effects [7-11]. Among known materials with α-glucosidase 
inhibitor activity, guava leaf extract and Touchi extract have been 
approved as individual authorized health functional foods to 
improve postprandial hyperglycemia [25] in Korea, and as Foods 
for Specified Health Use (FOSHU) in Japan [26]. In this study 
the fibrous root extract of the Welsh onion inhibited α-glucosidase 
in a dose-dependent manner with an IC50 of 239 μg/mL.
The inhibitory activity of the fibrous root extract against α
-glucosidase was further determined in STZ-induced diabetic rats 
using a carbohydrate load test. The fibrous root extract 
administered at a dose of 500 mg/kg showed significant suppressive 
effects on postprandial glucose levels at 30-120 min, and a 
reduction in the AUC of the glucose response curve by 54% 
(P< 0.01). These effects were comparable with those of acarbose, 
a competitive inhibitor of α-glucosidase given at 50 mg/kg.
Controlling not only fasting, but also postprandial hyperglycemia, 
is important in achieving tight control of blood glucose levels, 
which is the major target of diabetic therapy [4]. It was reported 
that postprandial hyperglycemia might be more strongly correlated 
with cardiovascular morbidity and mortality than fasting 
hyperglycemia [27]. Postprandial hyperglycemia has been shown 
to increase the production of free radicals, which induce 
vasoconstriction and stimulate prothrombotic pathways leading 
to an increased risk of cardiovascular disease, the major cause 
of premature death among type 2 diabetic patients [28]. Thus, 
the fibrous root extract of the Welsh onion may be beneficial 
in the management of diabetes.
The hypoglycemic effects of chronic consumption of Welsh 
onion fibrous root were compared with acarbose in db/db mice, 
which exhibit obesity, insulin resistance, and hyperglycemia. The 
fibrous root extract, consumed at 0.5% of the diet for 7 weeks, 
decreased fasting plasma glucose and HbA1c  by 32.0% and 
23.2%, respectively. Acarbose, which was given as a positive 
control at 0.05% of the diet, also reduced plasma glucose and 
HbA1c  (by 41.9% and 32.5%, respectively). These results, 
however, were not significantly different from those of the Welsh 
onion group. The average intakes of fibrous root extract and 
acarbose were calculated as 512 and 51 mg/kg/day, based on 490 Hypoglycemic effects of welsh onion
food intake and final body weight, respectively.
Clinical trials have shown that chronic consumption of 
acarbose effectively controls fasting hyperglycemia in type 2 
diabetic patients, which results from decreases in postprandial 
hyperglycemia [29-32]. It was suggested that reducing postprandial 
glucose elevations using an α-glucosidase inhibitor contribute to 
reductions in glucose toxicity, which leads to overall glycemic 
control [33]. It was also suggested that acarbose could increase 
insulin sensitivity in obese diabetic rats [34] and patients with 
type 2 diabetes [32]. It is possible that Welsh onion fibrous root 
extract could alleviate fasting hyperglycemia by reducing glucose 
toxicity and increasing insulin sensitivity.
HbA1c is considered to be a marker of long-term blood glucose 
control [35] and reflects both fasting plasma glucose and 
postprandial glucose [36]. Because HbA1c has strong predictive 
value for diabetic complications [37,38], reduced HbA1c in 
response to Welsh onion fibrous root treatment could contribute 
to a lower risk of diabetic complications. 
The data from this study suggest that the fibrous root of the 
Welsh onion has potential use as an effective hypoglycemic 
agent, rather than being discarded. Further studies aimed at 
isolating the active components in the extract are necessary to 
develop Welsh onion as a hypoglycemic agent.
In conclusion, the fibrous root of the Welsh onion alleviated fasting 
and postprandial hyperglycemia by inhibiting α-glucosidase in 
an animal model of diabetes. Thus, the fibrous root of the Welsh 
onion may be helpful in controlling blood glucose. 
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